Can Remicade (Infliximab) Cause Runny Nose and Cough?
Yes, Remicade (infliximab) can cause runny nose and cough, primarily as manifestations of upper respiratory tract infections, which are among the most common adverse events associated with this medication.
Understanding the Connection
Upper respiratory tract infections are consistently reported as one of the most frequent adverse reactions to infliximab therapy. The mechanism relates to infliximab's immunosuppressive effects—by blocking TNF-alpha, the drug reduces your immune system's ability to fight infections, making you approximately twice as likely to develop infections compared to baseline 1.
Frequency and Clinical Significance
According to FDA labeling data, upper respiratory tract infection occurs in 32% of patients treated with Remicade compared to 25% in placebo groups 2. Additional respiratory symptoms include:
- Pharyngitis: 12% of patients
- Sinusitis: 14% of patients
- Coughing: 12% of patients
- Bronchitis: 10% of patients
The British Association of Dermatologists guidelines specifically list upper respiratory tract infection, pharyngitis, sinusitis, and rhinitis as common adverse events with infliximab 3.
Clinical Approach to Respiratory Symptoms
When to Worry
You must distinguish between simple upper respiratory symptoms and serious infections. The American College of Chest Physicians guidelines emphasize that while most upper respiratory and urinary tract infections with infliximab are not serious, the risk of opportunistic infections is increased 1.
Seek immediate medical attention if you develop:
- Fever accompanying cough or runny nose
- Persistent symptoms beyond typical viral illness duration (>10-14 days)
- Worsening symptoms after initial improvement
- Shortness of breath or chest pain
- Productive cough with colored sputum
Critical Infections to Consider
The guidelines mandate specific vigilance for tuberculosis reactivation, which can present with chronic cough 1. Japanese case reports document both pneumocystis pneumonia and pulmonary tuberculosis occurring after multiple infliximab infusions 4. TB screening before initiating infliximab is mandatory, and any persistent respiratory symptoms warrant TB evaluation 2.
Management Strategy
For Mild Upper Respiratory Symptoms
If you develop simple runny nose and cough without fever or systemic symptoms:
- Continue infliximab - mild upper respiratory symptoms alone do not require discontinuation
- Monitor closely for progression to more serious infection
- Report symptoms to your physician before your next infusion
- Avoid live vaccines while on therapy 1
For Concerning Symptoms
Infliximab should not be started in the presence of active infection and should be discontinued if serious infection develops 1. The FDA label explicitly states patients should call their doctor immediately if they develop cough, fever, or flu-like symptoms 2.
Important Caveats
The timing matters: Infusion reactions occurring during or within 1-2 hours of infliximab administration can include respiratory symptoms (cough, dyspnea) as part of an acute hypersensitivity reaction 5, 6. These differ from infectious complications and require different management, including potential desensitization protocols 7.
Baseline disease considerations: Patients with underlying lung disease (COPD, sarcoidosis) receiving infliximab may have increased cancer risk and require heightened surveillance 3.
The evidence consistently demonstrates that while runny nose and cough are common with infliximab—primarily reflecting increased susceptibility to upper respiratory infections—most cases are mild and manageable. However, the immunosuppressive nature of the drug demands careful evaluation of any respiratory symptoms to exclude serious opportunistic infections.